In this article, we will discuss Ramucirumab (13). So, let’s get started.
Warnings-2
Arterial Thromboembolic Events
Serious, sometimes fatal, arterial thromboembolic events (ATEs) including myocardial infarction, cardiac arrest, cerebrovascular accident, and cerebral ischemia occurred in clinical trials including 1.7% of 236 patients who received Ramucirumab as a single agent for gastric cancer in clinical studies. Permanently discontinue Ramucirumab in patients who experience a severe ATE.